

Singapore grants interim authorisation for first bivalent COVID-19 booster vaccine

September 14, 2022 | News

Omicron-targeting bivalent booster candidate, mRNA-1273.214 (Spikevax) poised to be the next-generation vaccine offering a superior breadth of an immune response against Omicron BA.4 and BA.5



Singapore Health Sciences Authority (HSA) has granted an interim authorisation for the use of Moderna's Omicron-targeting bivalent booster vaccine. Also referred as Spikevax Bivalent Original/Omicron (mRNA-1273.214) is ahead in the race for active immunization to prevent COVID-19 disease in individuals 18 years of age and older.

Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains 25 µg of mRNA-1273 (Spikevax) and 25 µg of a vaccine candidate targeting the Omicron variant of concern (BA.1).

The Phase 2/3 Clinical trial data indicates mRNA-1273.214 proven for a superior neutralizing antibody response against Omicron (BA.1) when compared to the currently authorized 50 µg booster dose of Spikevax (mRNA-1273) in baseline seronegative participants.

Spikevax Bivalent Original/Omicron (mRNA-1273.214) elicited higher neutralizing antibody titers against the Omicron subvariants BA.4 and BA.5 when compared to Spikevax (mRNA-1273).

Moderna is working with the HSA and the Government of Singapore to make Spikevax Bivalent Original/Omicron available to people in Singapore during September. Moderna has received authorization decisions for omicron-targeting bivalent boosters in the United States, Australia, Canada, Europe, Japan, South Korea, Switzerland, Taiwan, and the UK to date and has completed regulatory submissions worldwide.